Fm 2007 Modifier 214 !!BETTER!!
Download >> DOWNLOAD
Fm 2007 Modifier 214
supplementary materials. (a) detailed description of analysis methods and results.
(b) detailed analysis and comparison results.
(c) results of meta-analysis in hd models in d. melanogaster.
(d) consistency of modifier identification in multiple experimental conditions in d.
(e) modifier identification results in a d. melanogaster model of hd.
(f) identification of genes as genetic modifiers in human and mouse.
figure s2. graphical representation of modifier and non-modifier gene searches. (a) graphical representation of modifier genes. the user can input the name of disease, model organism, disease model, etc., and will receive a list of all genes that are identified as modifiers. the gene names are hyperlinked, and the user can click on the gene of interest to search for detailed information, including gene function, potential mechanisms of action, and orthologs. (b) graphical representation of non-modifier genes., and will receive a list of all genes that are identified as non-modifiers.
figure s3. a ribbon diagram of hd modifier search in neurogem. (a) ribbon diagram for modifier search. the user can search for modifier genes by inputting a gene name, embl id, or organism, disease, and disease model. the search includes genes identified as modifiers or non-modifiers in experimental set-ups, which include a specific time point and drug. the data are visualized in a ribbon diagram.
figure s4. meta-analysis results for modifier genes in d. melanogaster. (a) fraction of genes that are modifiers, identified as non-modifiers, and non-modifiers in primary and secondary screens in hd models. the “x” stands for the number of disease models at each time point, ranging from 0 to 14 and beyond.
ii) many nd models rely on the genetic mutation of nd-related genes. however, the use of animal models of nd is ethically justified only for the identification of basic pathophysiological mechanisms. disease-modifying drugs should be tested in human patients.
iii) neurogem compiles the genes listed as modifiers in the primary screening that do not have a database counterpart. therefore, neurogem will facilitate the cross-linking of the genes modulated in different screening sets and may help to explore the underlying pathophysiology of these genes.
clicking on the record name at the bottom of the page leads to the display of an editing interface (figure 3 ). this interface allows the user to enter additional experimental information and retrieve additional experimental records that are related to the queried gene (figure 3 b). in addition to retrieving records based on gene names, the user can click on the title of any column header of a table displayed by neurogem to display the table for only a single gene. by dragging the table to the desired location in the screen, a new table page is created with the desired view of data. each table column header is associated with a color that indicates its type (column header). this color scheme is used in the record summary and details section of the page. figure 4 shows the complete set of type of modification, modus operandi, disease induction, and scale columns that are visible to the user in the editing interface that is displayed when a gene is selected in the record summary. table 1 shows the experimental records for the top-scoring gene, nup44a, that are available in neurogem. the corresponding biological details in d. melanogaster, c. elegans, and s. cerevisiae are also shown in the table.